FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005654938> ?p ?o ?g. }

• W2005654938 endingPage "1383" @default.
• W2005654938 startingPage "1378" @default.
• W2005654938 abstract "Transforming growth factor β (TGFβ) is a profibrotic cytokine, and its aberrant function is implicated in several types of fibrotic pathologies including scleroderma (systemic sclerosis [SSc]). Multiple lines of evidence show that increased TGFβ signaling contributes to progressive fibrosis in SSc by promoting fibroblast activation, excessive extracellular matrix (ECM) deposition, and dermal thickening. We have previously identified CD109 as a TGFβ coreceptor and have shown that it antagonizes TGFβ signaling and TGFβ-induced ECM expression in vitro in human keratinocytes and fibroblasts. The aim of the present study was to examine the ability of CD109 to prevent skin fibrosis in a mouse model of bleomycin-induced SSc.Transgenic mice overexpressing CD109 in the epidermis and their wild-type (WT) littermates were injected with bleomycin in phosphate buffered saline (PBS) or with PBS alone every other day for 21 days or 28 days. Dermal thickness and collagen deposition were determined histologically using Masson's trichrome and picrosirius red staining. In addition, collagen and fibronectin content was analyzed using Western blotting, and activation of TGFβ signaling was examined by determining phospho-Smad2 and phospho-Smad3 levels using Western blotting and immunohistochemistry.Transgenic mice overexpressing CD109 in the epidermis showed resistance to bleomycin-induced skin fibrosis, as evidenced by a significant decrease in dermal thickness, collagen crosslinking, collagen and fibronectin content, and phospho-Smad2/3 levels, as compared to their WT littermates.Our findings suggest that CD109 inhibits TGFβ signaling and fibrotic responses in experimental murine scleroderma. They also suggest that CD109 regulates dermal-epidermal interactions to decrease extracellular matrix synthesis in the dermis. Thus, CD109 is a potential molecular target for therapeutic intervention in scleroderma." @default.
• W2005654938 created "2016-06-24" @default.
• W2005654938 creator A5010718231 @default.
• W2005654938 creator A5029233463 @default.
• W2005654938 creator A5033337904 @default.
• W2005654938 creator A5050052540 @default.
• W2005654938 creator A5050155235 @default.
• W2005654938 creator A5081416946 @default.
• W2005654938 date "2013-04-23" @default.
• W2005654938 modified "2023-09-24" @default.
• W2005654938 title "Brief Report: CD109 Overexpression Ameliorates Skin Fibrosis in a Mouse Model of Bleomycin-Induced Scleroderma" @default.
• W2005654938 cites W1608423617 @default.
• W2005654938 cites W1976598253 @default.
• W2005654938 cites W1982925783 @default.
• W2005654938 cites W1996385150 @default.
• W2005654938 cites W2006568226 @default.
• W2005654938 cites W2015314604 @default.
• W2005654938 cites W2066256524 @default.
• W2005654938 cites W2076190000 @default.
• W2005654938 cites W2122758063 @default.
• W2005654938 cites W2122808924 @default.
• W2005654938 cites W2132546973 @default.
• W2005654938 cites W2135283213 @default.
• W2005654938 cites W2143616664 @default.
• W2005654938 cites W2735341948 @default.
• W2005654938 doi "https://doi.org/10.1002/art.37907" @default.
• W2005654938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23436317" @default.
• W2005654938 hasPublicationYear "2013" @default.
• W2005654938 type Work @default.
• W2005654938 sameAs 2005654938 @default.
• W2005654938 citedByCount "21" @default.
• W2005654938 countsByYear W20056549382013 @default.
• W2005654938 countsByYear W20056549382014 @default.
• W2005654938 countsByYear W20056549382015 @default.
• W2005654938 countsByYear W20056549382017 @default.
• W2005654938 countsByYear W20056549382018 @default.
• W2005654938 countsByYear W20056549382019 @default.
• W2005654938 countsByYear W20056549382020 @default.
• W2005654938 countsByYear W20056549382021 @default.
• W2005654938 countsByYear W20056549382022 @default.
• W2005654938 countsByYear W20056549382023 @default.
• W2005654938 crossrefType "journal-article" @default.
• W2005654938 hasAuthorship W2005654938A5010718231 @default.
• W2005654938 hasAuthorship W2005654938A5029233463 @default.
• W2005654938 hasAuthorship W2005654938A5033337904 @default.
• W2005654938 hasAuthorship W2005654938A5050052540 @default.
• W2005654938 hasAuthorship W2005654938A5050155235 @default.
• W2005654938 hasAuthorship W2005654938A5081416946 @default.
• W2005654938 hasBestOaLocation W20056549381 @default.
• W2005654938 hasConcept C104317684 @default.
• W2005654938 hasConcept C105702510 @default.
• W2005654938 hasConcept C118131993 @default.
• W2005654938 hasConcept C126322002 @default.
• W2005654938 hasConcept C134018914 @default.
• W2005654938 hasConcept C142724271 @default.
• W2005654938 hasConcept C180032290 @default.
• W2005654938 hasConcept C185592680 @default.
• W2005654938 hasConcept C189165786 @default.
• W2005654938 hasConcept C202751555 @default.
• W2005654938 hasConcept C2776232574 @default.
• W2005654938 hasConcept C2776458125 @default.
• W2005654938 hasConcept C2776694085 @default.
• W2005654938 hasConcept C2779967694 @default.
• W2005654938 hasConcept C2780381497 @default.
• W2005654938 hasConcept C2780559512 @default.
• W2005654938 hasConcept C2781080636 @default.
• W2005654938 hasConcept C55493867 @default.
• W2005654938 hasConcept C71924100 @default.
• W2005654938 hasConcept C85265743 @default.
• W2005654938 hasConcept C86492073 @default.
• W2005654938 hasConcept C86803240 @default.
• W2005654938 hasConcept C95444343 @default.
• W2005654938 hasConceptScore W2005654938C104317684 @default.
• W2005654938 hasConceptScore W2005654938C105702510 @default.
• W2005654938 hasConceptScore W2005654938C118131993 @default.
• W2005654938 hasConceptScore W2005654938C126322002 @default.
• W2005654938 hasConceptScore W2005654938C134018914 @default.
• W2005654938 hasConceptScore W2005654938C142724271 @default.
• W2005654938 hasConceptScore W2005654938C180032290 @default.
• W2005654938 hasConceptScore W2005654938C185592680 @default.
• W2005654938 hasConceptScore W2005654938C189165786 @default.
• W2005654938 hasConceptScore W2005654938C202751555 @default.
• W2005654938 hasConceptScore W2005654938C2776232574 @default.
• W2005654938 hasConceptScore W2005654938C2776458125 @default.
• W2005654938 hasConceptScore W2005654938C2776694085 @default.
• W2005654938 hasConceptScore W2005654938C2779967694 @default.
• W2005654938 hasConceptScore W2005654938C2780381497 @default.
• W2005654938 hasConceptScore W2005654938C2780559512 @default.
• W2005654938 hasConceptScore W2005654938C2781080636 @default.
• W2005654938 hasConceptScore W2005654938C55493867 @default.
• W2005654938 hasConceptScore W2005654938C71924100 @default.
• W2005654938 hasConceptScore W2005654938C85265743 @default.
• W2005654938 hasConceptScore W2005654938C86492073 @default.
• W2005654938 hasConceptScore W2005654938C86803240 @default.
• W2005654938 hasConceptScore W2005654938C95444343 @default.
• W2005654938 hasIssue "5" @default.
• W2005654938 hasLocation W20056549381 @default.
• W2005654938 hasLocation W20056549382 @default.

• next